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An intramolecular steroidal 1,2,4,5-tetraoxane has been synthesised in six steps start-
ing from methyl 3-oxo-7,12-diacetoxy-5-cholan-24-oate. The synthesised 1,2,4,5-tetra-
oxane has moderate in vitro antimalarial activity against P. falciparum strains (IC50 (D6) =
0.35 g/mL; IC50 (W2) = 0.29 g/mL).
Keywords: tetraoxane, malaria, peroxide, steroid, intramolecular.
INTRODUCTION
Tropical malaria, a major health problem in many southern countries, is caused by
multiplication of the protozoan parasite Plasmodium falciparum in erythrocytes. More
than 400 million disease cases with over 1.5 million deaths are the annual toll of P.
falciparum infections. Roll back malaria programs1 are hampered inter alia by the spread-
ing resistance of the parasite to standard antimalarial drugs, in particular to chloroquine
(CQ), which had been the affordable and effective antimalarial mainstay for 50 years. The
antimalarial properties of artemisinin2 and of other peroxides such as 1,2,4,5-tetraoxacy-
cloalkanes3 opened new avenues in the fight against malaria.
Our research in this area exploited the steroid carrier of cholestane4 and a cholic
acid-derived5 series: bis-steroidal tetraoxanes were explored. Now, the synthesis and pre-
liminary antimalarial activity of the first intramolecular steroidal tetraoxane derived from
cholic acid is presented.
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RESULTS AND DISCUSSION
Chemistry
The starting ketone 1was brominated using polymer-bound PyHBr3 (POLY-PyHBr3) in
acetic acid at 80 ºC (Scheme 1). As expected, the 4-bromo derivative 2was obtained (71 %)
which was further treated with hydrazine/AcOK6 in order to obtain directly the 3-alkene 4
needed for ring-opening to the dialdehyde6. Unfortunately, the reaction was sluggish and a sig-
nificant amount of unreacted2 remained. Thus, alkene47 was obtained by an alternative route
involving the reduction of bromoketone 2 into the epimeric bromohydrine mixture 3 (94 %;
(1:1)-ratio) which was further treated with Zn/AcOH (69 %). Oxidation of alkene 4 with
OsO4/NMO afforded the cis-diol 57 in 90 % yield. Oxidation with LTA/K2CO3 afforded the
desired dialdehyde 6 in 87 % yield, which was immediately used in the next step to avoid its
relatively fast polycondensation even at low temperatures.8
The peroxyacetalization reaction was carried out in a toluene / ethanol / water mixture
using 32 % H2O2 as described earlier.4 Based on spectral data, it was concluded that the
obtained tetraoxane 7 is a monomeric compound, i.e., the intramolecular tetraoxane was
obtained. Thus, the 13C-NMR spectrum excluded the existence of aldehyde functionality
(confirmed in 1H-NMR spectrum) and the two distinct C signals at 108.9 and 106.6 ppm
are indicative for peroxyacetal carbons (with differing neighbours). This, together with MS
(TOF) and m.a. data is sufficient for assigning the structure of 7 (Fig. 1).
Antimalarial activity
Tetraoxane was screened against Plasmodium falciparum D6 and W2 clones. D6 is a
clone from the Sierra I/UNC isolates and is susceptible to chloroquine and pyrimethamine,
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Scheme 1
but has reduced susceptibilities to mefloquine and halofantrine. W2 is a clone of the
Indochina I isolate and is resistant to chloroquine and pyrimethamine, but susceptible to
mefloquine.
The activity of 7 against both P. falciparum clones (IC50 (D6) = 0.35 g/mL; IC50
(W2) = 0.29 g/mL) is rather low as compared to other steroidal tetraoxanes of cholic
acid5 and artemisinin (IC50 (D6) = 2.37 ng/mL; IC50 (W2) = 2.06 ng/mL) but, interest-
ingly, it is more active against CQ resistant W2 clone, exhibiting similar IC50 (W2)/IC50
(D6) ratio (RI = 0.83) as artemisinin (RI = 0.82).
In conclusion, for the first time, an intramolecular steroidal tetraoxane with medium
antimalarial activity has been developed which gives a whole range of possibilities for fur-
ther structure (and acitivity) development, particularly of incorporation of other functio-
nalities into the steroid core and by altering the position of the tetraoxane moiety.
EXPERIMENTAL
General
Melting points were determined on a Boetius PMHK apparatus and were not corrected. Specific rota-
tions were determined on a Perkin-Elmer 141-MC instrument at the given temperatures. IR spectra were re-
corded on a Perkin-Elmer spectrophotometer FT-IR 1725X. 1H- and 13C-NMR spectra were recorded on a
Varian Gemini-200 spectrometer (at 200 and 50 MHz, respectively) in the indicated solvent using TMS as the
internal standard. Chemical shifts are expressed in ppm () values and coupling constants (J) in Hz.
EI and CI mass spectra were recorded on a MS Finnigan-MAT 8230 spectrometer with double focusing
reverse geometry, using isobutane (CI). Electrospray ionisation mass spectra were acquired on a QStar Pulsar
(Applied Biosystems) quadrupole-orthogonal time of flight (QqQ-TOF) hybrid instrument. The samples
were dissolved in pure acetonitrile (HPLC grade) to obtain a solution at 1.5 pmol/L concentration, which
was directly introduced into the ion source using a built-in syringe pump. Spectrum acquisition was made in
the positive ion mode in the mass range of m/z 300–1500 using the following ion source parameters: 5500 V
accelerating voltage, 100 V orifice voltage and 40 V skimmer voltage. The resolution of the instrument in the
TOF-MS mode was measured to be 8500 at 50 % valley definition.
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Fig. 1. The MM 2-optimised structure of tetraoxane 7. For clarity, the cholic acid side chain R is omitted.
Thin-layer chromatography (TLC) was performed on precoated Merck silica gel 60 F254 plates, using
N,N-dimethyl-p-phenylenediammonium dichloride reagent for peroxide moiety detection.9 Lobar LichroPrep Si
60 (40–63 m) columns coupled to a Waters RI 401 detector were used for column chromatography.
Methyl 4-bromo-3-oxo-7,12-diacetoxy-5-cholan-24-oate (2)
Amixture of 1 (10.10 g, 20 mmol) and polymer bound PyHBr.Br2 (10.0 g, 20 mmol; Fluka) in 500 mL
glacial acetic acid was stirred for 1 hour at 80 ºC. Then the reaction mixture was cooled, diluted with water,
left overnight, and filtered. The remaining solid was dissolved in CHCl3, and after removal of the polymer the
crude product was purified by dry-flash chromatography (eluent: toluene / EtOAc = 85 / 15). Yield 8.30 g (71
%), m.p. = 221–223 ºC (colourless prisms, benzene - hexane). D
20 = +92.20 (c = 1.00, CHCl3). IR (KBr):
3439m, 2961m, 2878w, 1737s, 1640w, 1436m, 1378m, 1314w, 1244s, 1222m, 1191m, 1176m, 1027m cm–1.
1H-NMR (200 MHz, CDCl3): 5.32 (d, J = 12.0 Hz, H-C(4)), 5.13 (s, H-C(12)), 5.07 (d, J = 2.8 Hz, H-C(7)),
3.67 (s, CH3O2C(24)), 2.13 (s, CH3COO–), 2.12 (s, CH3COO–), 1.08 (s, H3C-C(10)), 0.82 (d, J = 6.2 Hz,
H3C-C(20)), 0.78 (s, H3C-C(13)).
13C-NMR (50 MHz, CDCl3): 201.4, 174.4, 170.4, 170.1, 75.0, 70.1, 62.7,
52.5, 51.5, 45.0, 43.3, 37.8, 37.6, 36.0, 34.5, 30.7, 30.6, 30.2, 29.2, 27.0, 25.8, 22.6, 22.2, 21.5, 21.2, 17.4, 12.2
MS (DCI, m/z, %): 585 (M81Br)+, 1, 583 (M79Br)+, 1, 525 (M81Br)+ - AcOH, 12, 523 (M79Br)+ -
AcOH, 12, 505  (M79Br)H+ - 79Br, 2, 466 (M81Br)H+ – 2  AcOH, 40, 465 (M81Br)+ – 2  AcOH, 75,
464 (M79Br)H+ – 2  AcOH, 60, 463 (M79Br)+ – 2  AcOH, 100, 443 (M79Br)+ - AcOH - H79Br, 4, 385
(M79Br)H+ – 2  AcOH - 79Br, 10, 384 (M79Br)+ – 2  AcOH - 79Br, 10, 269 (0.5). Anal. calc. for
C29H43BrO7 (583.57): C 59.69, H 7.43. Found: C 59.82, H 7.34 %.
Methyl 4-bromo-3-hydroxy-7,12-diacetoxy-5-cholan-24-oate (3)
Solid NaBH4 (0.60 g, 16 mmol) was added over 30 min to an ice-cooled mixture of 2 (6.40 g, 11 mmol)
in MeOH (120 mL) under stirring. The reaction was quenched by 50 % acetic acid and poured onto an ice /
water mixture. After filtration and drying, the crude product was obtained (6.10 g, 94 %) and used in the next
step without further purification. 3-Hydroxy epimers (3a and 3b) were separated only for analytical purposes
by column chromatography (Lobar B, LichroPrep Si 60, eluent: heptane / EtOAc = 8 / 2).
Methyl 4-bromo-3-hydroxy-7,12-diacetoxy-5-cholan-24-oate (3a). Mp = 169–172 ºC (colourless
prisms, ether-hexane). IR (KBr): 3507s, 3483s, 3459s, 3235m, 2954m, 2876w, 1734s, 1636m, 1445m, 1379m,
1248s, 1027s cm–1. 1H-NMR (200 MHz, CDCl3): 5.09 (s, H-C(12)), 5.00–4.90 (m, H-C(4), H-C(7)), 4.15 (bs,
H-C(3)), 3.66 (s, CH3O2C(24)), 2.17 (s, CH3COO–), 2.12 (s, CH3COO–), 1.00 (s, CH3-C(10)), 0.81 (d, J = 6 Hz,
H3C-C(20)), 0.74 (s, H3C-C(13)).
13C-NMR (50 MHz, CDCl3): 174.5, 170.4, 75.3, 70.5, 66.8, 51.5, 47.3, 45.0,
43.8, 43.4, 38.6, 37.9, 34.5, 30.8, 30.7, 29.4, 28.7, 28.2, 27.1, 26.6, 25.7, 23.2, 22.6, 21.7, 21.3, 17.4, 12.2.
Methyl 4-bromo-3-hydroxy-7,12-diacetoxy-5-cholan-24-oate (3b). M.p. = 163–166 ºC (colourless
prisms, ether-hexane). IR (KBr): 3512s, 3499s, 3445s, 3410s, 2988m, 2954s, 2926s, 2861m, 1740m, 1707m,
1644w, 1452m, 1380m, 1274s, 1240s, 1080w, 1025m cm-1. 1H-NMR (200 MHz, CDCl3): 5.07 (s, H-C(12)),
4.97 (d, J = 3 Hz, H-C(7)), 4.67 (dd, J = 11.8 Hz, J = 9.8 Hz H-C(4)), 3.66 (s, CH3O2C(24)), 3.67–3.50 (m,
H-C(3)), 2.13 (s, CH3COO–), 2.12 (s, CH3COO–), 1.00 (s, H3C-C(10)), 0.80 (d, J = 6.2 Hz, H3C-C(20)), 0.73
(s, H3C-C(13)).
13C-NMR (50 MHz, CDCl3): 174.5, 170.4, 75.3, 70.5, 66.8, 51.5, 47.3, 45.0, 43.8, 43.4, 38.6,
37.9, 34.5, 30.8, 30.7, 29.4, 28.7, 28.2, 27.1, 26.6, 25.7, 23.2, 22.6, 21.7, 21.3, 17.4, 12.2.
Methyl 7,12-diacetoxy-5-chol-3-en-24-oate (4)
To a solution of 3 (6.50 g, 11 mmol) in glacial AcOH (190 mL) and H2O (9 mL), Zn powder (37.5 g) was
added within 30 min at 45–50 ºC. The reaction mixture was vigorously stirred until completion of the reaction.
After cooling and filtration, the solvent was removed under reduced pressure. The remaining viscous oil was dis-
solved in CHCl3, worked-up in the usual manner, dried over anh. Na2SO4 and evaporated to dryness. The crude
product was purified by dry-flash chromatography (eluent toluene / EtOAc = 9 / 1) and crystallised from hexane
to afford alkene 4. Yield 3.70 g (69 %), m.p. = 116–118 ºC (colourless prisms, hexane), lit. m.p. 115–116 ºC7.
D
20 = +18.78 (c = 1.00, CHCl3). IR (KBr): 3556m, 3507m, 3465s, 3410s, 2964m, 2923m, 1734s, 1619w,
1378m, 1253s, 1028wcm–1. 1H-NMR (200 MHz, CDCl3): 5.53 (dd, J = 10.1 Hz, J = 3 Hz, H-C(3)), 5.31 (dd, J
= 10 Hz, J = 1.6 Hz, H-C(4)), 5.08 (s, H-C(12)), 4.83 (d, J = 2.6 Hz, H-C(7)), 3.66 (s, CH3O2C(24)), 2.12 (s,
CH3COO–), 2.02 (s, CH3COO–), 0.95 (s, H3C-C(10)), 0.82 (d, J = 6 Hz, H3C-C(20)), 0.74 (s, H3C-C(13)).
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13C-NMR (50 MHz, CDCl3): 174.6, 170.8, 170.5, 133.0, 123.4, 75.6, 70.7, 51.5, 47.3, 44.9, 43.1, 41.5, 37.7,
34.6, 33.0, 32.9, 31.1, 30.8, 30.7, 28.3, 27.1, 25.7, 22.8, 22.1, 21.7, 21.2, 21.1, 17.5, 12.1. EI-MS , (m/z, %): 428
(M+-AcOH, 1), 368 (M+-2AcOH, 30), 315 (28), 282 (2), 253 (100), 227 (12), 199 (12), 145 (12), 84 (12), 43
(25). Anal. calcd. for C29H44O6 (488.67): C 71.28, H 9.08. Found: C 70.64, H 8.60 %.
Methyl 3,4-dihydroxy-7,12-diacetoxy-5-cholan-24-oate (5)
To a solution of alkene 4 (100 mg, 0.2 mmol) in an acetone / water mixture (4 mL; 4 / 1, v / v) were added
NMO.H2O (110 mg, 0.8 mmol) and a 2.5 % solution of OsO4 in t-BuOH (0.1 mL, 0.01 mmol). The mixture was
stirred at room temperature until completion of the reaction, followed by addition of NaHSO3 (10 mg) and fur-
ther stirring for a further 30 min. The acetone was removed under reduced pressure, brine was added and the
water layer was extracted with EtOAc (320 mL). The combined organic layers were washed with brine, dried
over anh. Na2SO4, and evaporated to dryness. The crude product was purified by column chromatography (Lo-
bar, LichroPrep Si 60, eluent: heptane / EtOAc = 3 / 7) and crystallized to afford the dihydroxy compound 5.
Yield 96 mg (90 %), m.p. = 83–85 ºC (colourless prisms, hexane-EtOAc), lit m.p. 74–76 ºC7. D
20 = +61.10 (c
= 1.00, CHCl3). IR (KBr): 3548m, 3490s, 2956m, 2877w, 1735s, 1705m, 1638w, 1439w, 1379m, 1254s,
1028m cm–1. 1H-NMR (200 MHz, CDCl3): 5.08 (s, H-C(12)), 4.91 (d, J = 2.6 Hz, H-C(7)), 4.05–3.95 (m,
H-C(3), H-C(4)), 3.66 (s, CH3O2C(24)), 2.11 (s, CH3COO–), 2.01 (s, CH3COO–), 0.96 (s, H3C-C(10)), 0.81 (d,
J = 6.0 Hz, H3C-C(20)), 0.74 (s, H3C-C(13)).
13C-NMR (50 MHz, CDCl3): 174.6, 170.6, 170.5, 75.4, 71.1,
70.9, 69.3, 51.5, 47.3, 45.0, 43.4, 42.7, 37.5, 36.1, 34.6, 30.8, 30.7, 29.7, 28.7, 27.1, 25.8, 24.8, 22.7, 21.6, 21.3,
21.0, 17.4, 14.1, 12.2. Anal. calcd. for C29H46O8
.H2O (540.70): C 64.42, H 8.95. Found: C 64.34, H 9.20 %.
Methyl 7,12-diacetoxy-3,4-dioxo-3,4-seco-5-cholan-24-oate (6)
To a stirred suspension of 5 (500 mg, 0.96 mmol) and anh. K2CO3 (280 mg, 2.0 mmol) in dry benzene
(20 mL) under argon, Pb(AcO)4 (440 mg, 0.99 mmol) was added in small portions within 1 h. The mixture
was stirred at room temperature for an additional 60 min, filtered through a sinter funnel and the remaining
solid was washed with benzene (80 mL). The filtrate was washed with sat. NaHCO3, water, brine and dried
over anh. Na2SO4. The crude product was used without further purification in the next reaction step. The ana-
lytical sample of the dialdehyde 6 was obtained upon column chromatography (Lobar A, LichroPrep Si 60,
eluent: toluene / EtOAc = 7/3). Yield 453 mg (87 %). IR (film): 3020m, 2956s, 2877m, 1733s, 1441m,
1378m, 1245s, 1025m cm–1. 1H-NMR (200 MHz, CDCl3): 9.87 (d, J = 2.2 Hz, HCO-C(5)), 9.73 (s,
HCO-C(2)), 5.11 (s, H-C(12)), 4.97 (d, J = 2.4 Hz, H-C(7)), 3.66 (s, CH3O2C(24)), 2.12 (s, CH3COO–), 2.02
(s, CH3COO–), 0.96 (s, H3C-C(10)), 0.81 (d, J = 6.2 Hz, H3C-C(20)), 0.76 (s, H3C-C(13)).
13C-NMR (50
MHz, CDCl3): 204.3, 201.4, 174.5, 170.4, 170.0, 74.8, 69.2, 52.3, 51.5, 47.3, 44.8, 43.0, 37.7, 36.5, 35.5, 34.5,
30.8, 30.6, 29.7, 29.6, 27.0, 26.0, 22.8, 21.3, 21.1, 18.8, 17.4, 12.1.
Methyl 7,12-diacetoxy-3,4-diperoxy-3,4-seco-5-cholan-24-oate (7)
To an ice-cooled mixture of 30 % H2O2 (0.23 mL, 2.1 mmol), EtOH (1.40 mL), H2O (1.32 mL) and conc.
H2SO4 (2.54 mL), a pre-cooled solution (ice-bath) of dialdehyde 6 (470 mg, 0.9 mmol) in 40 mL toluene was
added dropwise. After 30 min of stirring the reaction was quenched with water, the layers were separated and the
water layer was extracted with toluene (320 mL). The combined organic layers were washed with sat.
NaHCO3, brine, and dried over anh. Na2SO4. The solvent was removed under reduced pressure and the crude
product was purified by SiO2 chromatography (Lobar, LichroPrep Si 60, eluent heptane / EtOAc = 6/4) to afford
tetraoxane7.7: Yield 97 mg (19 %), m.p. = 108–111 ºC (colourless prisms, ether). D
20 = +101.07 (c = 1.03,
CHCl3). IR (KBr): 3452s, 2955m, 1736s, 1636w, 1442w, 1379m, 1244s, 1027s cm
–1. 1H-NMR (200 MHz,
CDCl3): 10.04, 9.88 (both s, residual acidic H, exchangeable with D2O), 5.79 (dd, J = 9.8 Hz, J = 3.2 Hz,
H-C(4)), 5.29 (s, H-C(3)), 5.05 (s, H-C(12)), 4.92 (d, J = 2 Hz, H-C(7)), 3.66 (s, CH3O2C(24)), 2.18 (s,
CH3COO–), 2.14 (s, CH3COO–), 0.99 (s, H3C-C(10)), 0.79 (d, J = 5.8 Hz, H3C-C(20)), 0.75 (s, H3C-C(13)).
13C-NMR (50 MHz, CDCl3): 174.7, 171.0, 170.6, 108.9, 106.6, 75.1, 69.8, 51.5, 44.8, 43.3, 43.1, 37.9, 37.1,
35.4, 34.5, 32.1, 31.8, 30.8, 30.6, 27.0, 26.3, 25.6, 22.6, 21.4, 21.2, 20.0, 17.4, 14.0, 12.1. ESI-MS (m/z, %):
625.24 (M + K+ + H2O2, 10), 609.28 (M + Na
+ + H2O2, 43), 603 (M + NH4
+ + H2O2, 8), 575.27 (M + Na
+,
8), 467.24 (6), 413.25 (3), 284.32 (100).
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Animalarial activity
The in vitro antimalarial drug susceptibility screen is a modification of the procedures first published by
Desjardins et al.,10 with modifications developed by Milhous et al..11 In brief, the assay relies on the incorpo-
ration of radiolabeled hypoxanthine into the parasites. The inhibition of isotope incorporation is attributed to
the activity of known or candidate antimalarial drugs. For each assay, proven antimalarials are used as con-
trols. The incubation period is 66 hours and the starting parasitemia is 0.2 % with 1 % hematocrit. The media
used is RPMI-1640 culture media with no folate or p-aminobenzoic acid (PABA) and 10 % normal heat inac-
tivated human plasma. For quantitative in vitro drug susceptibility testing, two well-characterized P.
falciparum malaria clones are normally used, W2 and D6.12 W2 is a clone of the Indochina I isolate and is re-
sistant to chloroquine and pyrimethamine, but susceptible to mefloquine. D6 is a clone from Sierra I/UNC
isolates and is susceptible to chloroquine and pyrimethamine, but has reduced susceptibilities to mefloquine
and halofantrine.
Acknowledgement: The authors from Belgrade are indebted to Mr. Milovan Stojanovi} for his kind as-
sistance.
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Polaze}i od metil-3-okso-7,12-diacetoksi-5-holan-24-oata sintetisan je u {est
faza intramolekulski steroidni 1,2,4,5-tetraoksan. Proizvod ima umerenu in vitro antima-
larijskuaktivnostpremaP. falciparum sojevima (IC50 (D6)=0.35g/mL; IC50 (W2)=0.29g/mL).
(Primqeno 28. februara 2002)
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